Month: March 2026

Being Published in the Journal of Vascular and Interventional Radiology, a Premier Peer-Reviewed Journal, Speaks to the Quality and Impact of the Study Company Remains Focused on Expanding Evidence-Based Data to Support Broader Commercial Adoption of the LIBERTY System HINGHAM, Mass., March 24, 2026 (GLOBE NEWSWIRE) — Microbot Medical Inc. (Nasdaq: MBOT), developer and distributor of the innovative LIBERTY® Endovascular Robotic System, which is already garnering medical and industry attention, today announced the publication of an article in the Journal of Vascular and Interventional Radiology (JVIR), titled “In Vivo Evaluation of a Disposable Endovascular Robotic System for Arterial Peripheral Vascular Interventions: A Multicenter Feasibility Study.” The article’s first author, Dr. Francois Cornelis, is a leading interventional...

VANCOUVER, British Columbia, March 24, 2026 (GLOBE NEWSWIRE) — GoldHaven Resources Corp. (“GoldHaven” or the “Company“) (CSE: GOH) (OTCQB: GHVNF) (FSE: 4QS) has completed a review of historical exploration data from three recently acquired mineral claims within its Magno Project in the Cassiar District of northern British Columbia. The claims, which expanded the property to over 37,200 hectares, host three historically explored mineral occurrences — a tungsten-molybdenum skarn at Lamb Mountain, an intrusion-related molybdenum system at Cassiar Moly, and a polymetallic volcanogenic massive sulphide (VMS) occurrence at Lang Creek — collectively demonstrating multiple mineralization styles within the broader Magno property. Highlights (Historical Data):Historical drilling at Lamb Mountain returned tungsten...

MIAMI, March 24, 2026 (GLOBE NEWSWIRE) — UMeWorld Inc. (OTCID: UMEW) today announced the completion of Phase I process engineering design for its pretreatment unit (“PTU”) under Project Verdant, in collaboration with COFCO Engineering. The completed process design establishes the technical foundation for the Company’s renewable fuels platform and supports the advancement of ongoing development, infrastructure planning, and capital structuring initiatives. The Phase I PTU is designed for approximately 450 metric tons per day of processing capacity, equivalent to approximately 150,000 metric tons per annum, and is expected to process a diversified range of waste-based lipid feedstocks, including palm oil mill-derived recovered oils (commonly referred to as POME oil), used cooking oil, animal fats, and other waste lipids, into refinery-ready...

The agreement includes approximately 330,000 Medicare Advantage members and more than 1.7 million commercial members in California, significantly expanding Rocket Doctor’s in-network reach across the state. Eligible members gain access to Rocket Doctor’s network of board-certified physicians, delivering primary care, chronic disease management, preventive services, and coordinated follow-up through its digital health platform and marketplace. The agreement builds on Rocket Doctor’s January 27, 2026 announcement, which expanded access to additional commercial members across California.Vancouver, BC, March 24, 2026 (GLOBE NEWSWIRE) — Rocket Doctor AI Inc. (CSE: AIDR, OTC: AIRDF, Frankfurt: 939) (“Rocket Doctor AI”) today announced that doctors using its wholly owned digital health platform and marketplace, Rocket Doctor Inc., are...

LAWRENCEVILLE, N.J., March 24, 2026 (GLOBE NEWSWIRE) — IMUNON, Inc. (Nasdaq: IMNN), a clinical-stage company in Phase 3 development with its DNA-mediated immunotherapy, today announced that the Company will host a conference call at 11:00 a.m. EDT on Tuesday, March 31, 2026 to discuss financial results for the year ended December 31, 2025, and provide an update on its clinical development program with IMNN-001, a DNA-based interleukin-12 (IL-12) immunotherapy. The Company is hosting a conference call to review 2025 financial results and provide a business update on March 31, 2026 at 11:00 a.m. EDT. To participate in the call, please dial 800-715-9871 (North America/Toll Free) or 646-307-1963 (U.S./Toll) and ask for the IMUNON Year End 2025 Financial Results Call (Conference ID 4157104). A live webcast of the call will also be available here. An...

Additional analyses from the SCORED and SOTA-P-CARDIA studies provide further evidence of benefits across patient subgroups potentially related to sotagliflozin’s mechanism of action THE WOODLANDS, Texas, March 24, 2026 (GLOBE NEWSWIRE) — Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX) today announced three presentations of sotagliflozin clinical data during the American College of Cardiology (ACC) Annual Meeting. The congress is being held March 28-30 in New Orleans, Louisiana. Lexicon will present data from the Phase 3 SCORED study of sotagliflozin in people with type 2 diabetes, chronic kidney disease and other cardiovascular risk factors. In a prespecified analysis, patients were stratified by baseline body mass index (BMI), and the results demonstrated that sotagliflozin reduced heart failure and major adverse cardiovascular...

Request omitted highly material disclosures required under the Company’s bylaws YZi Labs may not proceed with its proposed consent solicitation Stockholders are not required to take any action at this time LOUISVILLE, CO, March 24, 2026 (GLOBE NEWSWIRE) — CEA Industries Inc. (NASDAQ: BNC) (“BNC” or the “Company”) today announced that its Board of Directors (the “Board”) has completed its review of the request received from YZILabs Management Ltd. (“YZi Labs”) to set a record date for determining the stockholders entitled to consent in connection with YZi Labs’ proposed consent solicitation (the “Request Letter”). The Board has determined that YZi Labs’ Request Letter is deficient because it omitted material information required under the Company’s bylaws. Accordingly, the Board has not set a record date,...

AGOURA HILLS, Calif., March 24, 2026 (GLOBE NEWSWIRE) — Oncotelic Therapeutics, Inc. (OTCQB:OTLC) (“Oncotelic”, the “Company” or “We” or “Our”), a leader in RNA-based therapeutics, announced today that its subsidiary Sapu Nano will formally introduce its Deciparticle™ nanomedicine platform and present its advancing clinical pipeline at BIO-Europe Spring 2026, where the company has been selected as a Presenting Company. The presentation will take place at:Event: BIO-Europe Spring 2026 Session: Presenting Company Location: Theater A Date: March 25, 2026During the session, Sapu Nano will unveil its proprietary Deciparticle™ platform, a next-generation drug delivery technology engineered to optimize tissue distribution, enhance therapeutic index, and enable intravenous delivery...

RADNOR, Pa., March 24, 2026 (GLOBE NEWSWIRE) — Mineralys Therapeutics, Inc. (Nasdaq: MLYS), a biopharmaceutical company focused on developing medicines to target hypertension and related comorbidities such as chronic kidney disease (CKD), obstructive sleep apnea (OSA) and other diseases driven by dysregulated aldosterone, announced the appointment of Jeffrey A. Munsie as Chief Legal Officer. “Jeff brings deep life sciences experience across critical stages of growth, from preclinical through commercialization,” said Jon Congleton, Chief Executive Officer of Mineralys. “His strategic counsel, strong leadership, and proven track record will be instrumental in strengthening our legal and compliance capabilities.” Mr. Munsie joins Mineralys with nearly 25 years of comprehensive legal experience in the biopharma industry. Most recently,...